CN115671261A - Mixed peptide emulsion with sleep improvement effect and preparation method thereof - Google Patents
Mixed peptide emulsion with sleep improvement effect and preparation method thereof Download PDFInfo
- Publication number
- CN115671261A CN115671261A CN202211313927.1A CN202211313927A CN115671261A CN 115671261 A CN115671261 A CN 115671261A CN 202211313927 A CN202211313927 A CN 202211313927A CN 115671261 A CN115671261 A CN 115671261A
- Authority
- CN
- China
- Prior art keywords
- percent
- preparation
- improvement effect
- peptide emulsion
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 239000000839 emulsion Substances 0.000 title claims abstract description 21
- 230000006872 improvement Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 41
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 4
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 4
- 102000004142 Trypsin Human genes 0.000 claims abstract description 4
- 108090000631 Trypsin Proteins 0.000 claims abstract description 4
- 230000007062 hydrolysis Effects 0.000 claims abstract description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 4
- 229940111202 pepsin Drugs 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000012588 trypsin Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 33
- 239000011259 mixed solution Substances 0.000 claims description 15
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- 102000014171 Milk Proteins Human genes 0.000 claims description 6
- 108010011756 Milk Proteins Proteins 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000021239 milk protein Nutrition 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- -1 polydimethylsiloxane Polymers 0.000 claims description 4
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims description 3
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- JFSQSDAOQLNSQI-DTBJPNGVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-(hexadecanoylamino)-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O JFSQSDAOQLNSQI-DTBJPNGVSA-N 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 108010087806 Carnosine Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 241001071795 Gentiana Species 0.000 claims description 3
- 241000501743 Gentiana macrophylla Species 0.000 claims description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 241001530209 Swertia Species 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 3
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 3
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229910003472 fullerene Inorganic materials 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229940077272 palmitoyl hexapeptide-12 Drugs 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 229940047670 sodium acrylate Drugs 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 6
- 239000012528 membrane Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000036651 mood Effects 0.000 abstract description 4
- 230000000955 neuroendocrine Effects 0.000 abstract description 4
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 3
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 3
- 230000000147 hypnotic effect Effects 0.000 abstract description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract description 3
- 229960003987 melatonin Drugs 0.000 abstract description 3
- 210000002569 neuron Anatomy 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract description 3
- 108090000189 Neuropeptides Proteins 0.000 abstract description 2
- 102000003797 Neuropeptides Human genes 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of medical assistance, and discloses a mixed peptide emulsion with a sleep improvement effect and a preparation method thereof, wherein the preparation method comprises the following steps: s1, putting the raw materials in percentage into a reaction tank, and adding trypsin and pepsin into the reaction tank for hydrolysis. In work, the mixed peptide emulsion with the sleep improvement effect and the preparation method thereof have better biological membrane penetrability and stability by using the small molecular short peptide, can enter the center through the blood brain barrier to generate the neuropeptide effect, or directly act on receptors of nerve cell membranes to influence the synthesis and metabolism of neuroendocrine and neurotransmitter including melatonin and 5-hydroxytryptamine to generate the effects of stabilizing mood and calming and hypnosis.
Description
Technical Field
The invention belongs to the technical field of medical assistance, and particularly relates to a mixed peptide emulsion with a sleep improvement effect and a preparation method thereof.
Background
With the acceleration of the work and life rhythm of the modern society, great pressure causes people to enter a sub-health state, sleep disorders such as difficulty in falling asleep, insomnia, sleep structural disorder and the like appear, the sleep disorders are healthy enemies, and long-term sleep disorders can cause various damages to the body and seriously affect the physiology and physical and mental health, and are mainly expressed as follows: 1. the immunity of the organism is damaged, and the disease resistance is reduced; 2. causing hypertension, heart disease, and hyperlipidemia; 3. hypomnesis, headache, dizziness, tinnitus, neurasthenia, etc.; 4. abnormal mood, tension and irritability, depression, anxiety and low working efficiency, and serious emotional feeling can also lead to pessimism.
Sleep disorder, as intractable diseases, generally needs to be taken for a long time, and the treatment methods of drugs for improving sleep are various, and the administration of hypnotics is sought by many intractable insomnia patients, and the most treatment methods are the sedative hypnotic drugs such as diazepam, sulpiride, triazolam and the like;
however, the ingredients of the chemical drugs have addiction and dependence, and the addiction and dependence cannot completely help patients to treat insomnia, but can cause the problem of insomnia of the patients to be aggravated because the patients cannot get out of the normal sleep of the drugs; the traditional Chinese medicine and acupuncture therapy possibly has a certain symptom relieving effect in the early stage of insomnia, but the curative effect is not good enough for intractable insomnia and serious insomnia patients, and the curative effect cannot be achieved.
Disclosure of Invention
In view of the above situation, in order to overcome the defects of the prior art, the present invention provides a mixed peptide emulsion with sleep improvement effect and a preparation method thereof, which effectively solve the problems proposed in the background art.
In order to achieve the purpose, the invention provides the following technical scheme: a mixed peptide emulsion with sleep improvement effect comprises the following components in percentage by mass:
carbomer: 0.05 to 0.5 percent; propylene glycol: 0.5 to 5 percent; butanediol: 1 to 5 percent; glycerin: 1 to 10 percent; disodium salt: 0.01 to 0.1 percent; polysorbate-20: 0.5-3%; sodium acrylate/sodium acryloyldimethyl taurate copolymer: 0.3-2%; isohexadecane: 1 to 6 percent; polysorbate-80: 0.5 to 5 percent; polydimethylsiloxane: 0.5 to 5 percent; carnosine: 0.05 to 0.5 percent; dimethyl isosorbide anhydride: 0.05 to 3 percent; lactic acid bacteria/milk fermentation lysate: 0.05-3%; milk protein: 0.05-2%; extracting milk protein: 0.05 to 3 percent; milk amino acids: 0.05-3%; hydrogenated milk lipids: 0.03-3%; lactobacillus/milk/fermentation product filtrate: 0.03-3%; fullerene: 0.001-0.1%; soluble collagen cross-linked polymer: 0.001-0.1%; decapeptide-4: 0.001-0.1%; oligopeptide-1: 0.001-0.1%; oligopeptide-5: 0.001-0.1%; oligopeptide-2: 0.001-0.1%; tripeptide-1: 0.001 to 0.1 percent; acetyl tetrapeptide-5: 0.001 to 0.1 percent; acetyl hexapeptide-8: 0.001-0.1%; palmitoyl hexapeptide-12: 0.001-0.1%; sodium hyaluronate: 0.001 to 0.1 percent; decapeptide-4: 0.001-0.1%; aloe vera leaf juice: 0.5 to 5 percent; rutin is added: 0.01 to 0.5 percent; extract of gentiana macrophylla: 0.01 to 0.5 percent; the swertia extract: 0.01 to 0.5 percent; and (3) gentian extract: 0.01 to 0.5 percent; p-hydroxyacetophenone: 0.1 to 0.5 percent; 1, 2-hexanediol: 0.1-2%; ethyl hexyl glycerin: 0.02 to 0.2 percent; arginine: 0.02-0.2%.
Preferably, the mixed peptide emulsion with the sleep improvement effect and the preparation method thereof comprise the following steps:
s1, putting the raw materials in percentage into a reaction tank, and adding trypsin and pepsin into the reaction tank for hydrolysis;
s2, filtering, freezing and drying the hydrolyzed product to obtain pretreated reaction raw pulp, then adding the reaction raw pulp into a stirring reaction kettle, driving the stirring reaction kettle to stir the reaction raw pulp, adding a beta-cyclolawserine aqueous solution into the reaction raw pulp while stirring, and then homogenizing, freezing and drying to obtain a mixed solution A;
s3, adjusting the power of the stirring reaction kettle, reducing the power of the stirring reaction kettle, and adding a skin conditioner and a humectant into the mixed solution A to fully mix the skin conditioner and the humectant with the mixed solution A to obtain a mixed solution B;
s4, raising the temperature in the stirring reaction kettle, adding the emollient into the mixed solution B, uniformly stirring, adding the lysine emulsifier, the tyrosine emulsifier and the tryptophan tripeptide emulsifier, and uniformly stirring;
and S5, putting the container into an ice-water bath, applying a high-field intensity ultrasonic field on the outer side of the ice-water bath, and reacting for 5-10S to finally prepare the mixed peptide emulsion.
Preferably, the rotating speed of the stirring reaction kettle in the S2 is 200r/min-300r/min, and the rotating speed of the stirring reaction kettle in the S3 is 50r/min-100r/min.
Preferably, the temperature in the S4 is controlled to be 50-80 ℃, and the air pressure in the S4 is controlled to be 20-50 Mpa.
Preferably, the freeze-drying time in S2 is 4h-5h.
Preferably, the field intensity of the high-field-intensity ultrasonic field in S5 is 10-1000W-cm -2 。
Compared with the prior art, the invention has the beneficial effects that:
in work, the small molecular short peptide has better biological membrane penetrability and stability when being used, can enter the center through the blood brain barrier to generate a neuropeptide effect, or directly acts on receptors of a nerve cell membrane to influence the synthesis and metabolism of neuroendocrine and neurotransmitter including melatonin and 5-hydroxytryptamine to generate the effects of stabilizing mood and calming and hypnosis.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a schematic cross-sectional view of the present invention;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments; all other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In a first embodiment, as shown in fig. 1, the present invention includes a mixed peptide emulsion having a sleep improvement effect, the mixed peptide emulsion comprising the following components by mass:
carbomer: 0.05 to 0.5 percent; propylene glycol: 0.5 to 5 percent; butanediol: 1 to 5 percent; glycerol: 1 to 10 percent; disodium salt: 0.01 to 0.1 percent; polysorbate-20: 0.5 to 3 percent; sodium acrylate/sodium acryloyldimethyl taurate copolymer: 0.3 to 2 percent; isohexadecane: 1 to 6 percent; polysorbate-80: 0.5 to 5 percent; polydimethylsiloxane: 0.5 to 5 percent; carnosine: 0.05 to 0.5 percent; isosorbide dimethyl ether: 0.05-3%; lactic acid bacteria/milk fermentation lysate: 0.05-3%; milk protein: 0.05-2%; extracting milk protein: 0.05 to 3 percent; milk amino acids: 0.05-3%; hydrogenated milk lipids: 0.03-3%; lactobacillus/milk/fermentation product filtrate: 0.03 to 3 percent; fullerene: 0.001-0.1%; soluble collagen cross-linked polymer: 0.001-0.1%; decapeptide-4: 0.001-0.1%; oligopeptide-1: 0.001-0.1%; oligopeptide-5: 0.001-0.1%; oligopeptide-2: 0.001 to 0.1 percent; a tripeptide-1: 0.001-0.1%; acetyl tetrapeptide-5: 0.001-0.1%; acetyl hexapeptide-8: 0.001-0.1%; palmitoyl hexapeptide-12: 0.001-0.1%; sodium hyaluronate: 0.001-0.1%; decapeptide-4: 0.001-0.1%; aloe vera leaf juice: 0.5 to 5 percent; rutin is added: 0.01 to 0.5 percent; extract of gentiana macrophylla: 0.01 to 0.5 percent; the swertia extract: 0.01 to 0.5 percent; and (3) extracting gentian: 0.01 to 0.5 percent; p-hydroxyacetophenone: 0.1 to 0.5 percent; 1, 2-hexanediol: 0.1-2%; ethyl hexyl glycerin: 0.02 to 0.2 percent; arginine: 0.02-0.2%.
In a second embodiment, as shown in fig. 1, a mixed peptide emulsion having sleep improvement effect and a method for preparing the same, the method comprising the steps of:
s1, putting the raw materials in percentage into a reaction tank, and adding trypsin and pepsin into the reaction tank for hydrolysis;
s2, filtering, freezing and drying the hydrolyzed product to obtain pretreated reaction raw pulp, then adding the reaction raw pulp into a stirring reaction kettle, driving the stirring reaction kettle to stir the reaction raw pulp, adding a beta-cyclolakeol aqueous solution into the reaction raw pulp while stirring, and then homogenizing, freezing and drying to obtain a mixed solution A; the rotating speed of the stirring reaction kettle is 200r/min-300r/min, and the rotating speed of the stirring reaction kettle in the S3 is 50r/min-100r/min; the freeze drying time is 4-5 h;
s3, adjusting the power of the stirring reaction kettle, reducing the power of the stirring reaction kettle, and adding a skin conditioner and a humectant into the mixed solution A to fully mix the skin conditioner and the humectant with the mixed solution A to obtain a mixed solution B;
s4, raising the temperature in the stirring reaction kettle, adding the emollient into the mixed solution B, uniformly stirring, adding the lysine emulsifier, the tyrosine emulsifier and the tryptophan tripeptide emulsifier, and uniformly stirring; controlling the temperature to be 50-80 ℃, and controlling the air pressure in the S4 to be 20-50 Mpa;
s5, placing the container into an ice water bath, applying a high-field intensity ultrasonic field on the outer side of the ice water bath, and reacting for 5-10S to finally prepare a mixed peptide emulsion; the field intensity of the high-field intensity ultrasonic field is 10-1000W cm -2 。
In recent years, peptide sleep improvement medicines, particularly small molecule short peptides, have gradually attracted attention, the short peptides can influence the function of the central nervous system through a plurality of action mechanisms after entering blood circulation, some small molecule short peptides have better biomembrane penetrability and stability, can enter the center through the blood brain barrier to generate the effect of pseudoneuropeptide, or the small molecule short peptides directly act on receptors of nerve cell membranes to influence the synthesis and metabolism of neuroendocrine and neurotransmitter including melatonin and 5-hydroxytryptamine to generate the effects of stabilizing mood and tranquilizing and hypnotizing; in addition, the peptide mainly comprises amino acids, and after the small molecule mixed peptide is metabolized and decomposed in vivo, part of the amino acids enter the center to influence the synthesis and metabolism of neuroendocrine and neurotransmitter.
It should be noted that, in this document, relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (6)
1. A mixed peptide emulsion having a sleep-improving effect, characterized in that: the mixed peptide emulsion comprises the following components in percentage by mass:
carbomer: 0.05 to 0.5 percent; propylene glycol: 0.5 to 5 percent; butanediol: 1 to 5 percent; glycerol: 1 to 10 percent; disodium salt: 0.01 to 0.1 percent; polysorbate-20: 0.5-3%; sodium acrylate/sodium acryloyldimethyl taurate copolymer: 0.3-2%; isohexadecane: 1 to 6 percent; polysorbate-80: 0.5 to 5 percent; polydimethylsiloxane: 0.5 to 5 percent; carnosine: 0.05 to 0.5 percent; isosorbide dimethyl ether: 0.05-3%; lactic acid bacteria/milk fermentation lysate: 0.05 to 3 percent; milk protein: 0.05-2%; extracting milk protein: 0.05 to 3 percent; milk amino acids: 0.05-3%; hydrogenated milk lipids: 0.03-3%; lactobacillus/milk/fermentation product filtrate: 0.03-3%; fullerene: 0.001-0.1%; soluble collagen cross-linked polymer: 0.001-0.1%; decapeptide-4: 0.001-0.1%; oligopeptide-1: 0.001-0.1%; oligopeptide-5: 0.001 to 0.1 percent; oligopeptide-2: 0.001-0.1%; a tripeptide-1: 0.001 to 0.1 percent; acetyl tetrapeptide-5: 0.001-0.1%; acetyl hexapeptide-8: 0.001-0.1%; palmitoyl hexapeptide-12: 0.001-0.1%; sodium hyaluronate: 0.001 to 0.1 percent; decapeptide-4: 0.001-0.1%; aloe vera leaf juice: 0.5 to 5 percent; rutin is added: 0.01 to 0.5 percent; extract of gentiana macrophylla: 0.01 to 0.5 percent; the swertia extract: 0.01 to 0.5 percent; and (3) gentian extract: 0.01 to 0.5 percent; p-hydroxyacetophenone: 0.1 to 0.5 percent; 1, 2-hexanediol: 0.1-2%; ethyl hexyl glycerin: 0.02-0.2%; arginine: 0.02-0.2%.
2. The mixed peptide emulsion with sleep improvement effect and the preparation method thereof according to claim 1, characterized in that: the preparation method comprises the following steps:
s1, putting the raw materials in percentage into a reaction tank, and adding trypsin and pepsin into the reaction tank for hydrolysis;
s2, filtering, freezing and drying the hydrolyzed product to obtain pretreated reaction raw pulp, then adding the reaction raw pulp into a stirring reaction kettle, driving the stirring reaction kettle to stir the reaction raw pulp, adding a beta-cyclolawserine aqueous solution into the reaction raw pulp while stirring, and then homogenizing, freezing and drying to obtain a mixed solution A;
s3, adjusting the power of the stirring reaction kettle, reducing the power of the stirring reaction kettle, and adding a skin conditioner and a humectant into the mixed solution A to fully mix the skin conditioner and the humectant with the mixed solution A to obtain a mixed solution B;
s4, raising the temperature in the stirring reaction kettle, adding the emollient into the mixed solution B, uniformly stirring, adding the lysine emulsifier, the tyrosine emulsifier and the tryptophan tripeptide emulsifier, and uniformly stirring;
and S5, putting the container into an ice-water bath, applying a high-field intensity ultrasonic field outside the ice-water bath, and reacting for 5-10S to finally prepare the mixed peptide emulsion.
3. The mixed peptide emulsion with sleep improvement effect and the preparation method thereof according to claim 1, characterized in that: the rotating speed of the stirring reaction kettle in the S2 is 200r/min-300r/min, and the rotating speed of the stirring reaction kettle in the S3 is 50r/min-100r/min.
4. The mixed peptide emulsion with sleep improvement effect and the preparation method thereof according to claim 1, characterized in that: the temperature in the S4 is controlled to be 50-80 ℃, and the air pressure in the S4 is controlled to be 20-50 Mpa.
5. The mixed peptide emulsion with sleep improvement effect and the preparation method thereof according to claim 1, characterized in that: the time for freeze drying in the S2 is 4-5 h.
6. The mixed peptide emulsion with sleep improvement effect and the preparation method thereof according to claim 1, characterized in that: the field intensity of the high-field intensity ultrasonic field in the S5 is 10-1000W-cm -2 。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211313927.1A CN115671261A (en) | 2022-10-25 | 2022-10-25 | Mixed peptide emulsion with sleep improvement effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211313927.1A CN115671261A (en) | 2022-10-25 | 2022-10-25 | Mixed peptide emulsion with sleep improvement effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671261A true CN115671261A (en) | 2023-02-03 |
Family
ID=85099750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211313927.1A Withdrawn CN115671261A (en) | 2022-10-25 | 2022-10-25 | Mixed peptide emulsion with sleep improvement effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671261A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017883A (en) * | 2023-08-25 | 2023-11-10 | 广州帝臣生物科技股份有限公司 | Deoiling shampoo and preparation method thereof |
-
2022
- 2022-10-25 CN CN202211313927.1A patent/CN115671261A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017883A (en) * | 2023-08-25 | 2023-11-10 | 广州帝臣生物科技股份有限公司 | Deoiling shampoo and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3930808B2 (en) | Yeast-derived functional peptide having anti-stress function, anti-fatigue function, premenstrual syndrome and menstrual pain alleviating function and function as neurotrophic factor and method for producing the same | |
| CN105662916B (en) | Composition for repairing sebum membrane | |
| CN115671261A (en) | Mixed peptide emulsion with sleep improvement effect and preparation method thereof | |
| CN108210689A (en) | A kind of canker sore film containing hyaluronic acid and preparation method thereof | |
| EA029649B1 (en) | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof | |
| US8715650B2 (en) | Bathing composition and method for preparing same | |
| CN109700998B (en) | Compound skin injury regeneration repairing agent and preparation method thereof | |
| CN101129413A (en) | Polyzyme emulsifying method of traditional Chinese medicine | |
| CN106036325A (en) | Fructus lycii enzyme and preparation method thereof | |
| CN112807416A (en) | Traditional Chinese medicine bone peptide composition with function of improving bone joint health and preparation method thereof | |
| CN117089590A (en) | Royal jelly protein peptide and preparation method and application thereof | |
| CN110664666A (en) | Multi-effect cream for promoting skin fibroblasts to secrete structural proteins | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| CN106539804A (en) | A kind of molecule traditional Chinese medicine frostlike-powder for relief from osteoarthritis pain and preparation method thereof | |
| CN100515390C (en) | Anterior pituitary adrenocortical extract nano-liposome composite medicine, its preparation method and use | |
| CN103898629B (en) | A kind of polyster fibre possessing health care | |
| JPH10114665A (en) | Improver for aqueous body fluid and composition for oral administration comprising the same | |
| CN105995971A (en) | Nutritional liquid food for promoting diabetes recovery and preparation method thereof | |
| CN102058617B (en) | Sodium heparin vitamin E gel and preparation method thereof | |
| CN1814077A (en) | Medicinal liquor for treating hemorrhoids | |
| CN111643486A (en) | Huperzine A acupoint sustained-release gel patch for treating senile dementia and preparation method thereof | |
| CN115350260B (en) | Daily care biological agent with sleep-aiding function for skin and preparation method thereof | |
| KR102358574B1 (en) | Composition For Improving Bowel Movement Comprising Cricket or Extract Thereof | |
| CN102727776B (en) | Externally-applied weight-reducing liquid and preparation method thereof | |
| CN110787287B (en) | Application of fish scale collagen polypeptide in preparation of medicine for treating chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230203 |
|
| WW01 | Invention patent application withdrawn after publication |